21st week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110123402 | CARBONATE SPRING PRODUCING SYSTEM - A carbonate spring producing system includes a gas-liquid separator ( | 2011-05-26 |
20110123403 | AIR POLLUTION CONTROL APPARATUS AND AIR POLLUTION CONTROL SYSTEM - An air pollution control apparatus | 2011-05-26 |
20110123404 | Start-Up Heater for Ammonia Reactors - An internal start-up heater ( | 2011-05-26 |
20110123405 | Pyrolysis Reactor Conversion of Hydrocarbon Feedstocks Into Higher Value Hydrocarbons - In one aspect, the inventive process comprises a process for pyrolyzing a hydrocarbon feedstock containing nonvolatiles in a regenerative pyrolysis reactor system. The inventive process comprises: (a) heating the nonvolatile-containing hydrocarbon feedstock upstream of a regenerative pyrolysis reactor system to a temperature sufficient to form a vapor phase that is essentially free of nonvolatiles and a liquid phase containing the nonvolatiles; (b) separating said vapor phase from said liquid phase; (c) feeding the separated vapor phase to the pyrolysis reactor system; and (d) converting the separated vapor phase in said pyrolysis reactor system to form a pyrolysis product. | 2011-05-26 |
20110123406 | HYDROCARBON CONVERSION PROCESS - A process is provided to produce an ultra low sulfur diesel with less than about 10 ppm sulfur using a two-phase or liquid-phase continuous reaction zone to convert a diesel boiling range distillate preferably obtained from a mild hydrocracking unit. In one aspect, the diesel boiling range distillate is introduced once-through to the liquid-phase continuous reaction zone over-saturated with hydrogen in an amount effective so that the liquid phase remains substantially saturated with hydrogen throughout the reaction zone as the reactions proceed. | 2011-05-26 |
20110123407 | RAPID THERMAL CONVERSION OF BIOMASS - The present invent provides improved rapid thermal conversion processes for efficiently converting wood, other biomass materials, and other carbonaceous feedstock (including hydrocarbons) into high yields of valuable liquid product, e.g., bio-oil, on a large scale production. In an embodiment, biomass material, e.g., wood, is feed to a conversion system where the biomass material is mixed with an upward stream of hot heat carriers, e.g., sand, that thermally convert the biomass into a hot vapor stream. The hot vapor stream is rapidly quenched with quench media in one or more condensing chambers located downstream of the conversion system. The rapid quenching condenses the vapor stream into liquid product, which is collected from the condensing chambers as a valuable liquid product. In one embodiment, the liquid product itself is used as the quench media. | 2011-05-26 |
20110123408 | APPARATUS FOR PRODUCING SILICON - To provide a structure for mounting a novel reaction tube, which is capable of following up the thermal expansion of the reaction tube without the need of hanging down the reaction tube in the apparatus for producing silicon. In a reaction unit | 2011-05-26 |
20110123409 | CHEMICAL REACTOR WITH NANOMETRIC SUPERSTRUCTURE - The invention relates to a chemical reactor with a nanometric superstructure, comprising at least one member wherein at least one reaction chamber is arranged, and said reaction chamber being filled at least partially with a high specific surface area material having a specific surface area greater than 5 m | 2011-05-26 |
20110123410 | COMPACT DEVICE FOR MIXING FLUIDS IN A DOWNFLOW REACTOR - A compact device for mixing fluids in a downflow reactor comprising at least one substantially horizontal gathering device provided with a vertical gathering line intended to receive the fluids, at least one injection device arranged in the gathering line, an annular mixing chamber located downstream from the gathering means in the direction of circulation of the fluids, the mixing chamber comprising an inlet end directly connected to the gathering line and an outlet end for passage of the fluids, and a horizontal predistribution plate comprising at least one chimney, the plate being located downstream from the mixing chamber at a distance d | 2011-05-26 |
20110123411 | SYNTHESIS OF OLIGOMERS IN ARRAYS - Systems, including apparatus and methods, for synthesis of oligomers in arrays. | 2011-05-26 |
20110123412 | Centerpipe Design for Radial Flow Reactor - A device is presented for use as a centerpipe in a radial flow reactor, or for a radial flow adsorption bed. The device includes a plurality of stacked slotted cylindrical sections and frustums. The design retains the particles in a solid particulate bed that can be flowing through the reactor. The frustums provide covers to the cylindrical sections to prevent the flow of solid particles back through the slots in the cylindrical sections. | 2011-05-26 |
20110123413 | SURFACES, INCLUDING MICROFLUIDIC CHANNELS, WITH CONTROLLED WETTING PROPERTIES - The present invention generally relates to coating materials, including photoactive coating materials. In some aspects of the invention, a sol-gel is provided that can be formed as a coating on a microfluidic channel. One or more portions of the sol-gel can be reacted to alter its hydrophobicity, in some cases. For instance, in one set of embodiments, a portion of the sol-gel may be exposed to light, such as ultraviolet light, which can be used to induce a chemical reaction in the sol-gel that alters its hydrophobicity. In one set of embodiments, the sol-gel can include a photoinitiator, that upon exposure to light, produces radicals. Optionally, the photoinitiator may be conjugated to a silane or other material within the sol-gel. The radicals so produced may be used to cause a polymerization reaction to occur on the surface of the sol-gel, thus altering the hydrophobicity of the surface. In some cases, various portions may be reacted or left unreacted, e.g., by controlling exposure to light (for instance, using a mask). Such treated surfaces within a microfluidic channel may be useful in a wide variety of applications, for instance, in the creation of emulsions such as multiple emulsions. | 2011-05-26 |
20110123414 | MULTILAYER CONTAINERS - A multilayer evacuated blood collection tube is provided having a first tube layer, and a second tube layer formed on the first tube layer and a closure, the second tube layer being a nanocomposite barrier layer. Such containers include but are not limited to blood collection tubes, evacuated blood collection tubes, centrifuge tubes, culture bottles, and syringe barrels. | 2011-05-26 |
20110123415 | Microplate and methods for making the same - A microplate ( | 2011-05-26 |
20110123416 | RACK WITH VIAL - A sample vial [ | 2011-05-26 |
20110123417 | EXHAUST GAS TREATMENT DEVICE - A device for treatment of exhaust gases includes a housing, a fragile structure resiliently mounted within the housing, and a non-intumescent mounting mat disposed in a gap between the housing and the fragile structure. The mounting mat includes a plurality of inorganic fibers that have undergone a surface treatment to increase the holding force performance of the mounting mat. Also disclosed are methods of making a mounting mat for an exhaust gas treatment device and for making an exhaust gas treatment device incorporating the mounting mat. | 2011-05-26 |
20110123418 | Process for Forming High Density Sulfides - A process for the recovery of a metal sulfide from a metal ion containing solution, including the steps of: a) providing a slurry containing seed panicles of said metal sulfide; h) adding a sulfide ion containing solution to said slurry to form an activated seed slurry; c) mixing said activated seed slurry with said metal ion containing solution to thereby form a metal sulfide precipitate; and d) recovering said metal sulfide precipitate. | 2011-05-26 |
20110123419 | METHOD FOR PREPARING MANGANESE SULFATE AND ZINC SULFATE FROM WASTE BATTERIES CONTAINING MANGANESE AND ZINC - A method for preparing manganese sulfate and zinc sulfate from waste batteries containing manganese and zinc, and more particularly to a method for preparing manganese sulfate and zinc sulfate from waste batteries containing manganese and zinc. Zinc powder and activated carbon are added to a leached solution obtained from a continuous leaching process so as to remove heavy metals and organic materials from the leached solution, and then the leached solution is spray-dried to simultaneously obtain manganese sulfate and zinc sulfate at high-purity by a simple process without generating wastewater. An environmentally friendly waste battery recycling process is thereby provided, because it is not required to use additional chemical substances for neutralization titration or impurity removal in recovering manganese sulfate and zinc sulfate by leaching a waste battery powder. | 2011-05-26 |
20110123420 | PROCESS FOR THE FORMULATION OF POTASSIUM CHLORIDE FROM A CARNALLITE SOURCE - A process for formulating high purity potassium chloride from a carnallite source. The process takes advantage of solubility differences and saturation levels in a multiple salt system generated upon dissolution of carnallite. In the system, the sodium chloride is kept in solution and the magnesium chloride present in the system is controlled to be in a concentration range of between 12% and 25% by weight. This avoids co-precipitation of sodium chloride with the potassium chloride during crystallization and therefore prevents the sodium chloride from contaminating the potassium chloride. The result is high grade potassium chloride. | 2011-05-26 |
20110123421 | ZONED CATALYZED SOOT FILTER - The present invention relates to a catalyzed soot filter which comprises a wall flow substrate with an inlet end, an outlet end, a substrate axial length extending between the inlet end and the outlet end, and a plurality of passages defined by internal walls of the wall flow substrate wherein the plurality of passages comprise inlet passages having an open inlet end and a closed outlet end, and outlet passages having a closed inlet end and an open outlet end, and wherein the internal walls of the inlet passages comprise a zoned first inlet coating, the internal walls of the outlet passages comprise a zoned first outlet coating, and wherein the first inlet coating and the first outlet coating are present on the wall flow substrate at a coating loading ratio of less than 0.5. | 2011-05-26 |
20110123422 | Flue Gas Scrubbing - Herein is disclosed a flue gas scrubbing composition, a method of using the flue gas scrubbing composition, and a method of entombing mercury collected with the flue gas scrubbing composition. The flue gas scrubbing composition includes an admixture of a mercury sorbent material that comprises a clay, copper, and sulfur; and lime that comprises calcium oxide and/or calcium hydroxide. The method of collecting mercury from a flue gas includes injecting the flue gas scrubbing composition of any one of the preceding claims into a flue duct comprising the flue gas; reacting the mercury sorbent material with mercury in the flue gas to form a mercury-sorbed material and thereby reducing the concentration of mercury in the flue gas; reacting the lime with SO | 2011-05-26 |
20110123423 | PHOTOCATALYTIC FLUIDIZED BED REACTOR WITH HIGH ILLUMINATION EFFICIENCY FOR PHOTOCATALYTIC OXIDATION PROCESSES - The invention relates to the realization of synthesis of organic compounds or abatement of volatile organic compounds (VOCs) in gas-solid fluidised bed photocatalytic reactor with improved illumination efficiency. The photoreactor consists of a two-dimensional fluidized bed catalytic reactor with two walls transparent to ultraviolet radiation, by an illumination system bases on a matrix of LEDs positioned near its external walls, and heated for Joule effect inside the catalytic bed to monitor the reaction temperature. Surprisingly, through the choice of a suitable catalyst and fluidized bed photoreactor operating conditions both total and partial oxidation reactions can be achieved with high activity and selectivity. Even more surprisingly, the value of the illuminated catalyst surface area per unit irradiated volume reaches values in the order of 10 | 2011-05-26 |
20110123424 | PROCESS FOR THE PHASE TRANSFORMATION OF SUBSTANCES - Process for the phase transformation of substances and mixtures of substances, in which the substance or the mixture of substances is introduced into a plasma reactor, the substance or the mixture of substances is converted into the higher-energy phase and the product is removed in gaseous form from the plasma reactor. The process can be used for the sublimation of metal salts, metal nitrates and/or metal alkoxides and other vaporizable metal organic compounds. | 2011-05-26 |
20110123425 | GaN Whiskers and Methods of Growing Them from Solution - Millimeter-scale GaN single crystals in filamentary form, also known as GaN whiskers, grown from solution and a process for preparing the same at moderate temperatures and near atmospheric pressures are provided. GaN whiskers can be grown from a GaN source in a reaction vessel subjected to a temperature gradient at nitrogen pressure. The GaN source can be formed in situ as part of an exchange reaction or can be preexisting GaN material. The GaN source is dissolved in a solvent and precipitates out of the solution as millimeter-scale single crystal filaments as a result of the applied temperature gradient. | 2011-05-26 |
20110123426 | MAGNETIC POWDER SUITABLE FOR LOW-NOISE MEDIA - An iron system magnetic powder, and particularly an iron system magnetic powder comprised chiefly of Fe | 2011-05-26 |
20110123427 | PRODUCTION OF LITHIUM COMPOUNDS DIRECTLY FROM LITHIUM CONTAINING BRINES - Methods and apparatus for the production of low sodium lithium carbonate and lithium chloride from a brine concentrated to about 6.0 wt % lithium are disclosed. Methods and apparatus for direct recovery of technical grade lithium chloride from the concentrated brine are also disclosed. | 2011-05-26 |
20110123428 | METHOD AND SYSTEM FOR PRODUCING CALCIUM CARBIDE - A method and a system for producing calcium carbide, the method including mixing powdery carbon-containing raw material with powdery calcium-containing raw material, and directly heating the mixture by combusting a part of carbon-containing raw material in an oxygen-containing atmosphere to produce calcium carbide. The carbon-containing raw material can be coal, semi-coke or coke, the calcium-containing raw material can be calcium carbonate, calcium oxide, calcium hydroxide or carbide slag. The system includes a raw material preheating unit, such as a fluidized bed or an entrained flow bed, and a reaction unit such as an entrained flow bed. By combustion of the by-product CO produced during the production of calcium carbide or auxiliary fuel in the air to preheat the raw materials to 500-1500° C., the carbon consumption and the oxygen consumption for the calcium carbide production can be reduced, and thus process energy consumption is further reduced. | 2011-05-26 |
20110123429 | Process for Producing Carbon Nanotubes from Renewable Raw Materials - A subject of the present invention is a process for producing carbon nanotubes, the process comprising:
| 2011-05-26 |
20110123430 | METHOD OF CONCENTRATING OZONE GAS AND APPARATUS THEREFOR - A method of concentrating ozone gas in which, although the apparatus configuration is simple, ozone gas of a predetermined concentration can be efficiently taken out, and an apparatus therefor are provided. In a method of concentrating ozone gas in which an ozone-oxygen mixture gas is acted in an adsorbing column that is filled with an adsorbent, to cause the adsorbent to selectively adsorb the ozone gas, and the selectively adsorbed ozone gas is desorbed, thereby concentrating and purifying the ozone gas, the ozone-oxygen mixture gas is acted on the adsorbent in a non-cooled state to cause the ozone gas to be selectively adsorbed to the adsorbent, the adsorbing column is vacuumed when performing an operation desorbing of the ozone gas, thereby desorbing the ozone gas from the adsorbent, and an initial amount of the leading out of the desorbed ozone gas is not recovered, thereby obtaining high-concentration ozone gas. | 2011-05-26 |
20110123431 | THERMALLY SPRAYED AL2O3 LAYERS HAVING A HIGH CONTENT OF CORUNDUM WITHOUT ANY PROPERTY-REDUCING ADDITIVES, AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to thermally sprayed Al | 2011-05-26 |
20110123432 | HYDRATE FORMATION FOR GAS SEPARATION OR TRANSPORT - A gas separation or gas transportation process forms a gas hydrate from an aqueous feed and a gas feed having a hydrate P-T stability envelope. While in the presence of the aqueous feed, the gas feed is initially pressurized to an operating pressure and cooled to an operating temperature which are inside the hydrate P-T stability envelope to form a gas hydrate from at least a portion of the gas feed and at least a portion of the aqueous feed. The resulting gas hydrate is readily separable from any remaining gas and stable for transport. | 2011-05-26 |
20110123433 | METHOD FOR MAKING ALUMINOSILICATE ZSM-12 - An aluminosilicate ZSM-12 may be prepared de novo in a small crystalline form from a reaction mixture containing a source of silica and a source of alumina. A small crystalline form of aluminosilicate ZSM-12 may also be prepared from a small crystalline form of borosilicate ZSM-12 by replacement of boron in the borosilicate ZSM-12 framework with aluminum. The aluminosilicate ZSM-12 is useful as an isomerization selective catalyst in processes such as isomerization dewaxing hydrocarbon feedstocks. | 2011-05-26 |
20110123434 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER - The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments. | 2011-05-26 |
20110123435 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY - The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity. Formula I | 2011-05-26 |
20110123436 | Dock-and-Lock (DNL) Complexes for Delivery of Interference RNA - Described herein are compositions and methods of use of targeted delivery complexes for delivery of siRNA to a disease-associated cell, tissue or pathogen. The targeted delivery complex comprises a targeting molecule, such as an antibody or fragment thereof, conjugated to one or more siRNA carriers. In preferred embodiments the siRNA carrier is a dendrimer or protamine and the targeting molecule is an anti-cancer antibody, such as hRS7. More preferably, the antibody or fragment is rapidly internalized into the target cell to facilitate uptake of the siRNA. Most preferably, the targeted delivery complex is made by the DNL technique. The compositions and methods are of use to treat a variety of disease states, such as cancer, autoimmune disease, immune dysfunction, cardiac disease, neurologic disease, inflammatory disease or infectious disease. | 2011-05-26 |
20110123438 | UNIVERSAL ANCHOR PEPTIDE FOR NANOPARTICLES - The present invention provides a substantially non-lytic, non-cytotoxic anchor peptide that is capable of stably inserting into lipid membranes. In particular, the invention provides nanoparticles comprising stably inserted anchor peptides, which may be conjugated to a variety of different cargo complexes. | 2011-05-26 |
20110123439 | Dual-Modality PET/MRI Contrast Agents - The present invention relates a dual-modality PET (positron emission tomography)/MRI (magnetic resonance imaging) contrast agent, a hybrid nanoparticle comprising: (a) a magnetic signal generating core; (b) a water-soluble multi-functional ligand coated on the signal generating core; and (c) a positron emitting factor linked to the water-soluble multi-functional ligand. The contrast agent of the present invention is the dual-modality contrast agent enabling to perform PET and MR imaging and can effectively obtain images having the merits of PET (excellent sensitivity and high temporal resolution) and MR (high spatial resolution and anatomical information) imaging. The contrast agent of the present invention is very useful for non-invasive and highly sensitive real-time fault-free imaging of various biological events such as cell migration, diagnosis of various diseases (e.g., cancer diagnosis) and drug delivery. | 2011-05-26 |
20110123440 | Altered Antibody FC Regions and Uses Thereof - The present invention relates to altered antibody Fc regions and uses thereof. | 2011-05-26 |
20110123441 | NOVEL GREB1A MONOCLONAL ANTIBODY - The generation and validation of a novel monoclonal GREB1 antibody (GREB1ab). Methods for the prognosis, diagnosis, assessment of disease progression, severity and outcome utilize GREB1 molecules as biomarkers. The GREB1 antibody is also a useful tool for investigations focused on the expression, distribution and function of GREB1 in normal and cancer tissues. | 2011-05-26 |
20110123442 | Tumor specific antibodies and uses therefor - Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject. | 2011-05-26 |
20110123443 | PANCREATIC BETA-CELL MASS BIOMARKER - A biomarker for pancreatic beta-cell mass comprising measuring the levels of CFC1 in the serum of a subject is described. The biomarker provides a noninvasive means for measuring pancreatic beta cell mass that is particularly useful for monitoring the efficacy of treatments for metabolic disorders such as Type I or Type II diabetes, including pancreatic islet cell transplantations. | 2011-05-26 |
20110123444 | Use of radioactively labelled molecule specifically binding to ED-B fibronection in a method of treatment of Hodgkin lymphoma - The invention relates to the use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment for patients with Hodgkin lymphoma, in particular primary refractory Hodgkin lymphoma or recurrent Hodgkin lymphoma after chemotherapy, and for Hodgkin lymphoma patients scheduled for primary combined-modality therapy. | 2011-05-26 |
20110123445 | TREATMENT MONITORING - The present invention provides a method for monitoring the effectiveness of atreatment, wherein said treatment comprises an inhibitor designed to treat a disease comprising abnormal activity of the Ras/Raf/MEK/ERK pathway. | 2011-05-26 |
20110123446 | DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material. | 2011-05-26 |
20110123447 | METHOD OF PROVIDING HUMAN TUMOR-SPECIFIC ANTIBODIES - Provided are novel tumor-specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigens and that are obtained from a tumor patient who shows at least partial clinical response or is symptom-free. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of tumors are described. | 2011-05-26 |
20110123448 | OIL BODY CARRIERS, USES IN TARGET THERAPY AND/OR DETECTION OF THE SAME, AND FUSION PROTEINS COMPRISED THEREIN - An oil body carrier, its uses in target therapy and/or detection, and a fusion protein comprised therein are provided. The oil body carrier comprises: | 2011-05-26 |
20110123449 | Solid Forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(- Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide - The present invention relates to substantially crystalline and solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide (Form A-HCl, Form B, Form B-HCl, or any combination of these forms), pharmaceutical compositions thereof, and methods of treatment therewith. | 2011-05-26 |
20110123450 | MACROCYCLIC CYANINE AND INDOCYANINE BIOCONJUGATES PROVIDE IMPROVED BIOMEDICAL APPLICATION - The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized photoacoustic, and sonofluorescence imaging, detection and therapy of tumors and other abnormalities. | 2011-05-26 |
20110123451 | Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin - This invention describes a method for delivery of a therapeutic agent to target cells. Liposome delivery vesicles binds to a specific cell population via a targeting molecule attached to the liposome surface. After the liposomes bind to a target cell they are internalized into compartments within the cell called endosomes. It has been shown by prior art that by encapsulating a pore forming bacterial hemolysin into the lumen of a liposome, the endosome is broken down and drug is delivered into the cell cytoplasm. Instead of encapsulating the hemolysin within the liposome, this invention improves on current techniques by associating the hemolysin with the lipid membrane of the liposome. This modification reduces development cost significantly, eases production methods and increases the effectiveness and versatility of the treatment. Using this technique, we have demonstrated effective targeting and killing of Her-2 overexpressing tumor cells. | 2011-05-26 |
20110123452 | METAL OLIGOMERS AND POLYMERS AND THEIR USE IN BIOLOGY AND MEDICINE - Described herein are a class of metal oligomers and polymers that contain both metals and organic groups. Said oligomers and polymers have utility in many applications including biomedical imaging, radiation therapy, drug delivery, and in vitro analytical techniques, such as fluorescence and phosphorescence. | 2011-05-26 |
20110123453 | Polyoxazolines with Inert Terminating Groups, Polyoxazolines Prepared from Protected Initiating Groups and Related Compounds - The present disclosure provides novel functional polyoxazoline derivatives prepared by terminating polyoxazoline polymerization with inert chemical groups. In addition, the present disclosure demonstrates the synthesis of novel electrophilic initiators with protected functional groups capable of initiating oxazoline polymerization and capable of surviving the conditions of polymerization. These initiators are used to synthesize the above inert-terminal polyoxazoline derivatives as well as other poly-oxazolines with active terminal groups. Furthermore, the present disclosure provides for polyoxazoline-lipid conjugates and liposomal compositions prepared using such polyoxazoline-lipid conjugates. Methods of using the foregoing to prepare conjugates with target molecules are also disclosed. | 2011-05-26 |
20110123454 | Method for modulating appetite - The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject. | 2011-05-26 |
20110123455 | RATIONAL DESIGN OF REGENERATIVE MEDICINE PRODUCTS - The present invention concerns a non-biased, combinatorial approach to the identification of components that modulate a regenerative response in a target tissue, thereby restoring or partially restoring homeostasis to the target tissue. The methods of the present invention are based on in vivo testing, with or without prior in vitro predictive functional testing or combinatorial testing. | 2011-05-26 |
20110123456 | HOLLOW BIODEGRADABLE NANOSPHERES AND NANOSHELLS FOR DELIVERY OF THERAPEUTIC AND/OR IMAGING MOLECULES - A polymeric hollow nanoshell or nanosphere for release of an agent is described, wherein the hollow nanosphere comprises at least one biodegradable polymer, characterised in that the polymer is cross-linked. The biodegradable mono-disperse nanospheres described are suitable for use as carriers of biomolecules, therapeutic agents and/or imaging agents. | 2011-05-26 |
20110123457 | CONJUGATES OF 19F MR IMAGING TRACERS AND CHEMOTHERAPEUTIC AGENTS FOR DRUG QUANTIFICATION AND DRUG DOSE INDIVIDUALIZATION - A therapeutic agent formed of a magnetic resonance imaging tracer conjugated with a chemotherapeutic agent. The therapeutic agents can be used in measuring drug delivery to a target tissue. The therapeutic agents allow for therapeutic MRI, in which | 2011-05-26 |
20110123458 | POLYMER-METAL COMPLEX COMPOSITE HAVING MRI CONTRAST ABILITY AND MRI CONTRASTING AND/OR ANTITUMOR COMPOSITION USING THE SAME - The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. | 2011-05-26 |
20110123459 | Anaerobic Iodine Solution - In accordance with the present invention, iodine, an iodine derivative(s), or a combination of a plurality of these substances is presented as the active ingredient of a stable naturopathic liquid solution. More specifically, in addition to the active ingredient, the naturopathic solution will include a liquid carrier that has been saturated with an inert gas (e.g. Nitrogen) to improve the stability of the active ingredient and increase the shelf life of the solution. For the manufacture of the solution, a liquid carrier (e.g. purified distilled water) is degassed and then subsequently saturated with the inert gas. The active ingredient is then added to the saturated liquid carrier to create the naturopathic liquid solution. | 2011-05-26 |
20110123460 | PHARMACEUTICAL FORMULATION FOR TREATING THE UPPER DIGESTIVE TRACT - The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time. | 2011-05-26 |
20110123461 | Compositions and Methods for the Maintenance of Oral Health - The invention provides compositions comprising one or more isolated LDH-deficient | 2011-05-26 |
20110123462 | BIOFILM DISRUPTIVE COMPOSITIONS - In certain embodiments, the present invention relates to compounds, compositions, and methods for disrupting biofilms. In some embodiments, the compounds and compositions comprise unsaturated long chain alcohols and/or aldehydes, or combinations of such compounds. In further embodiments, the present invention contains therapeutic actives to help reduce and/or eradicate the bacteria in the biofilm once the film is disrupted. | 2011-05-26 |
20110123463 | TOPICAL COMPOSITIONS - A topical composition, e.g. pharmaceutical or cosmetic composition comprising at least one cyclodextrin complex of a marine unsaturated fatty acid or derivative thereof wherein the weight ratio of cyclodextrin to marine fatty acid or derivative thereof is between 1:10 and 10:1. | 2011-05-26 |
20110123464 | STABILIZATION OF BODY-CARE AND HOUSEHOLD PRODUCTS - Described is the use of specific lactone compounds for protecting body-care and household products from photolytic and oxidative degradation. These compounds perform outstanding antioxidant properties. | 2011-05-26 |
20110123465 | LOW-IRRITATION COMPOSITIONS AND METHODS OF MAKING THE SAME - Provided are compositions comprising low molecular weight polymeric materials and surfactants having reduced irritation associated therewith, methods of reducing the irritation associated with a personal care composition comprising an anionic and/or amphoteric surfactant, the methods comprising combining a low molecular weight polymeric material capable of binding a surfactant thereto with an anionic surfactant to produce a reduced irritation personal care composition, and methods of using such compositions to cleanse the hair or skin with reduced irritation. | 2011-05-26 |
20110123466 | PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING AN ACTIVE PRINCIPLE ACTIVATOR OF CYTOCHROME C - A cosmetic or pharmaceutical, and in particular a dermatological one, including, in physiologically adapted medium, an active principle capable of activating cytochrome C. This active principle may be composed of polypeptides or of peptides, used alone or in association with at least one other active principle. This active principle may also be included in a cosmetic composition intended to stimulate the functions of the mitochondria and to increase the cellular energy level. The active principle be also be used in a cosmetic-treatment procedure intended to protect the skin and the appendages from external aggressions and to combat cutaneous aging. | 2011-05-26 |
20110123467 | COMPOSITIONS FOR PROMOTING A HEALTHY APPEARANCE OF THE SKIN - Topical skin care compositions are provided for the improvement of the appearance of the skin, namely of the skin comprising the face, surrounding the eyes, mouth, and hands, as well as the skin of the body. The skin care compositions include synergistic combinations of active peptide ingredients that are specially formulated to enhance the natural appearance of the face, hands, and/or body. Specifically, the synergistic skin care compositions may be applied to one or more of the skin surrounding the eyes, mouth, nose, forehead, ears, neck, hands, feed, and overall body to give the skin thereof a cleaner, smoother and more wrinkle free appearance. | 2011-05-26 |
20110123468 | USE OF BENZOTROPOLONE DERIVATIVES AS UV ABSORBERS AND ANTIOXIDANTS AND THEIR USE IN SUNSCREENS AND/OR COSMETIC COMPOSITIONS - Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R | 2011-05-26 |
20110123469 | Method for Producing Vitamin D in a Person - A method for enhancing production of Vitamin D within a person's skin includes a source of Vitamin D, a sunlight exposure indicator, and a sunscreen. Vitamin D, for example, cod liver oil, is applied to the skin topically via a patch or towlette, or ingested orally. The exposure indicator is worn by the user and changes its state to indicate that the person has been exposed to sunlight for a predetermined period of time. The user preferably waits a sufficient time for the Vitamin D to be absorbed into the skin, and then exposes his or her skin to direct sunlight, and monitors the exposure indicator to determine if it has changed state. The user applies the sunscreen to the user's skin after the exposure indicator changes state. | 2011-05-26 |
20110123470 | NATURAL BIOACTIVE COMPOUNDS - The present invention relates to butenolide compounds having cytoprotection such as antioxidant, anti-inflammatory and/or antifungal properties, and which are derived from the marine fungus | 2011-05-26 |
20110123471 | Topical Composition with Skin Lightening Effect - A topical cosmetic composition for increasing skin whitening or lightening is described. The composition includes a pomegranate extract in an amount effective to reduce melanin composition. The pomegranate extract may be standardized to about 20% punicalagin. The composition may also include an extract from the genus | 2011-05-26 |
20110123472 | LONG WEAR COSMETIC COMPOSITION - The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers. | 2011-05-26 |
20110123473 | USE OF HIGHLY-BRANCHED POLYCARBONATES IN COSMETIC AND DERMATOLOGICAL FORMULATIONS - The present invention relates to compositions which comprise highly-branched polycarbonates, to the use of these highly-branched polycarbonates in cosmetics and dermatology and to substituted highly-branched polycarbonates. | 2011-05-26 |
20110123474 | Non-Visible Activated Carbon in Absorbent Materials - The present invention teaches an absorbent material with powdered activated carbon which is substantially light-colored without using color masking agents or hiding. This invention addresses the need in the field for an absorbent material with improved odor-controlling properties, that maintains such properties for longer periods of time and where the absorbent material maintains a light-colored appearance without the addition of color-masking agents. Suitable methods for creating the absorbent materials include a pan agglomeration process, a high shear agglomeration process, a low shear agglomeration process, a high pressure agglomeration process, a low pressure agglomeration process, a rotary drum agglomeration process, a pan agglomeration process, a roll press compaction process, a pin mixer process, a dry blending process, a spray coating process, an extrusion process, a pelletizing process and a fluid bed process. | 2011-05-26 |
20110123475 | COATING COMPOSITION COMPRISING AN ANTIMICROBIAL COPOLYMER - The invention relates to a coating composition comprising an antimicrobial hydrophilic copolymer consisting of a macromer and a comonomer, the use of said coating composition in medical applications and, in particular in a medical device and to a medical device comprising the coating composition, preferably selected from catheters, endoscopes, laryngoscopes, tubes for feeding or drainage or endotracheal use or oesophageal use. The coating composition can further comprise a hydrophilic polymer, a polyelectrolyte and a photo-initiator. | 2011-05-26 |
20110123476 | Adhesive Formulations - The disclosure relates to biocompatible components useful for forming compositions for use as medical/surgical synthetic adhesives and sealants. Biocompatible components of the present disclosure may include a multifunctional amine or multifunctional polyol core, with isocyanate and/or polyalkylene oxide arms, which may optionally be capped with electrophilic or nucleophilic groups. These biocompatible components may, in embodiments, be combined with optional cross linkers to form adhesive and/or sealant compositions. | 2011-05-26 |
20110123477 | METHOD AND COMPOSITIONS FOR BIOFOULING DETERRENCE - A method of deterring biofouling of a surface comprising attaching an adduct having formula (I) or noradrenalin to the surface. Formula (I) being defined as compounds that have the formula A-L-R wherein A is i) a C6 or C10 substituted aryl ring, or ii) a C1-C9 substituted or unsubstituted heteroaryl ring: L is a linking group, and R is a primary amino moiety comprising unit. | 2011-05-26 |
20110123478 | BINDER FOR ANTIFOULING COATING COMPOSITION AND ANTIFOULING COATING COMPOSITION COMPRISING BINDER - The present invention relates to silyl ester copolymers useful as binders in antifouling coating compositions and antifouling coating compositions comprising the silyl ester copolymers. The silyl ester copolymers comprise repeating units of monomers A, B and optionally C. A is one or more monomers selected from the group consisting of triorganosilyl esters of polymerisable ethylenically unsaturated carboxylic acids. B is one or more monomers selected from the group consisting of lactone modified hydroxyalkyl (meth)acrylates, and C is one or more monomers selected from the group consisting of polymerisable ethylenically unsaturated compounds. | 2011-05-26 |
20110123479 | MEDICAL ADHESIVES FOR STOPPING HEAVY BLEEDING AND SEALING LEAKAGES - The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) | 2011-05-26 |
20110123480 | CHIMERIC PROTEINS AND USES THEREOF - The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof. | 2011-05-26 |
20110123481 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS - A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm | 2011-05-26 |
20110123482 | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide - Described herein are methods for treating neurological autoimmune disorders in which the treatment method includes administering an immunoablative agent to eliminate most or essentially all maturing and mature elements of the immune system in an affected individual. Following this step, the individual is administered agents to reestablish the ablated immune system. | 2011-05-26 |
20110123483 | HMGB1 FOR CANCER TREATMENT - The current invention relates to a method for treating a subject suffering from cancer comprising administering to said subject a therapeutically effective dose of High Mobility Group B1 (HMGB1) protein or of a polynucleotide comprising a coding region for an HMGB1 gene in an expressible form. Moreover, it relates to the combination of said method with other cancer treatment regimens. | 2011-05-26 |
20110123484 | METHODS AND COMPOSITIONS FOR TREATING FUS1 RELATED DISORDERS - The invention relates to methods, systems, and transgenic animals useful for screening, diagnosing, and treating Fus1 related disorders. Further disclosed herein are novel methods for inhibiting cellular proliferation disorders as well as immune system disorders. | 2011-05-26 |
20110123485 | VIRAL VECTORS FOR DELIVERING VACCINES FOR HIV AND OTHER INFECTIOUS DISEASES - The invention relates in some aspects to recombinant gamma herpes viruses that expresses immunodeficiency virus antigens. Some aspects of the invention relate to vaccine compositions and formulations comprising recombinant gamma herpes viruses that expresses immunodeficiency virus antigens. In some aspects, the invention relates to methods for preventing or treating an immunodeficiency virus associated disease. In some aspects, the invention relates to methods for preventing or treating AIDS. | 2011-05-26 |
20110123486 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS - Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents. | 2011-05-26 |
20110123487 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistence in the body, solubility, and bioavailability. | 2011-05-26 |
20110123488 | Method of Treatment for Cancers Associated with Elevated HER2 Levels - Novel methods of treating proliferative disorders characterized by elevated Her-2, and the patient is then administered an effective amount of an HSP90 inhibitor. | 2011-05-26 |
20110123489 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein | 2011-05-26 |
20110123490 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein R | 2011-05-26 |
20110123491 | METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST CHLAMYDIAL INFECTION AND DISEASE - The present invention provides | 2011-05-26 |
20110123492 | IMMUNITY-INDUCING AGENT - The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo. | 2011-05-26 |
20110123493 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS - Pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (Ia): wherein, R | 2011-05-26 |
20110123494 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2011-05-26 |
20110123495 | DERIVATIVES OF PYRIDONE AND USE THEREOF - The present invention provides N-substituted-2(1H) pyridones or the pharmaceutical acceptable salts thereof, and the pharmaceutical preparations containing the compounds. The compounds of the present invention can be used to treat various fibrotic diseases effectively, e.g., hepatic fibrosis. | 2011-05-26 |
20110123496 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2011-05-26 |
20110123497 | GRAFT COMPOSITION FOR NEURAL TISSUE REGENERATION, METHOD OF PRODUCTION AND USES THEREOF - The present invention provides a biocompatible, biodegradable graft composition for regeneration of neural tissue, comprising the following components: a) a gel scaffold formed from an isolated platelet containing fluid and an activating agent comprising calcium chloride, with or without thrombin, b) a nerve growth factor selected from BDNF, NGF, retinoic acid and combinations thereof, and c) a culture of at least 50,000 progenitor stem cells; the method of production and the uses thereof. | 2011-05-26 |
20110123498 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 2011-05-26 |
20110123499 | CELLULAR DIFFERENTIATION PROMOTION - Neural precursor cells can be encouraged to form mature neural cells twice as quickly in the absence, or reduced expression of, thymosin β4. | 2011-05-26 |
20110123500 | METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF - The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells. | 2011-05-26 |
20110123501 | GUT FLORA AND WEIGHT MANAGEMENT - The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of proteobacteria, preferably gamma-proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabolic disorders, to support weight loss and/or to support weight management. | 2011-05-26 |
20110123502 | METHOD FOR OBTAINING TREG-CELLS - A method for generating a population of functional regulatory T cells (T | 2011-05-26 |